Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):917–924. doi: 10.1038/bjc.1996.457

Evaluation of phenylpiperazines as targeting agents for neuroblastoma.

J W Babich 1, W A Graham 1, A J Fischman 1
PMCID: PMC2074721  PMID: 8826858

Abstract

The potential of radiolabelled phenylpiperazines as agents for the detection and therapy of tumours of neural crest origin was evaluated by in vitro pharmacological studies with human neuroblastoma cell lines [SK-N-SH and SK-N-BE(2C)], and in vivo by biodistribution measurements. The ability of phenylpiperazines: 4-phenyl-piperazine (PP), 1-carboxamidino-4-phenyl-piperazine (CAPP), [4-(3-chlorophenyl)-piperazine (mCPP), 4-(3-trifluoro methyl phenyl)-piperazine (TFMPP), and (1,1-dimethyl-4-phenyl)-piperazinium hydrochloride (DMPP) and chlorophenyl hydroxypiperidine [CP(OH)P], to inhibit MIBG uptake by neuroblastoma cells was determined by incubation with [125I]MIBG (0.1 microM) for 2 h in the presence of varying concentrations (10(-8)-10(-3) M) of ligand. For measuring uptake, cells were incubated with [125I]IPP (0.1 microM) and cell-associated radioactivity was measured at various times. Retention was studied by incubating cells in the presence of [125I]IPP (0.1 microM) for 2 h, followed by replacement with drug-free medium and determination of cell-bound radioactivity. Selectivity of [125I]IPP uptake was studied by inhibition studies with MIBG, DMI, 5HT and phenylpiperazines. The biodistribution of [125I]IPP was measured in normal rats at 0.083, 0.5, 1, 2 and 24 h (six animals per group). The IC50S (microM) for inhibition of [125I]MIBG uptake were: PP, 1.5; CPP, 2.5; CAPP, 2.5; DMPP, 5; CP(OH)P, 30 and TFMPP, 65. The rate of cellular uptake of [125I]IPP was greatest between 0 and 60 min and decreased after 60 min, similar to MIBG. After an initial rapid washout of approximately 50% of the radioactivity, retention remained constant for 3 h. The IC50S (microM) for inhibition of [125I]IPP uptake were: MIBG, 18-25; DMI, 0.6-1.5; 5HT, > 100; IPP, 1.8-2.5; CPP, 7.0-9.0 and TFMPP, > or = 20. The in vivo studies demonstrated a pattern of distribution similar to MIBG. The results demonstrate that phenylpiperazines display significant affinity for neuroblastoma with uptake and retention characteristics similar to MIBG.

Full text

PDF
917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuzar S., Sharma S. Synthesis of 2-carbalkoxyamino-5(6)-(1-substituted piperazin-4-yl/piperazin-4-ylcarbonyl)benzimidazoles and related compounds as potential anthelmintics. Pharmazie. 1984 Nov;39(11):747–749. [PubMed] [Google Scholar]
  2. Bagdy G., Szemeredi K., Kanyicska B., Murphy D. L. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. J Pharmacol Exp Ther. 1989 Jul;250(1):72–78. [PubMed] [Google Scholar]
  3. Biedler J. L., Spengler B. A., Ross R. A. Cellular maturation and oncogene expression during drug-induced differentiation in vitro: a brief review. Prog Clin Biol Res. 1990;354A:287–312. [PubMed] [Google Scholar]
  4. Chumpradit S., Kung H. F., Billings J., Guo Y. Z., Wu Y., Shih J. Preparation and biodistribution of 1-[2-(3-[125I]iodo-4-aminophenyl)ethyl]-4-[3-(trifluoromethyl) phenyl]piperazine and 1-[2-(3-[125I]iodo-4-azidophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl] piperazine. J Med Chem. 1989 Mar;32(3):543–547. doi: 10.1021/jm00123a006. [DOI] [PubMed] [Google Scholar]
  5. Elmaleh D. R., Padmanabhan S., Hassan M. A., Correia J. A., Herman L. W., Hanson R. N., Strauss H. W. Synthesis and evaluation of 1-[11C]methyl-4-aryl-piperazinium salts as myocardial imaging agents. Nucl Med Biol. 1993 May;20(4):427–433. doi: 10.1016/0969-8051(93)90073-4. [DOI] [PubMed] [Google Scholar]
  6. Fraser S. E., Bronner-Fraser M. Migrating neural crest cells in the trunk of the avian embryo are multipotent. Development. 1991 Aug;112(4):913–920. doi: 10.1242/dev.112.4.913. [DOI] [PubMed] [Google Scholar]
  7. Fuller R. W. Substituted phenylpiperazines as serotonin agonists: structural determinants of potency and interaction with receptor subtypes. Psychopharmacol Bull. 1986;22(3):825–828. [PubMed] [Google Scholar]
  8. Gildersleeve D. L., Lin T. Y., Wieland D. M., Ciliax B. J., Olson J. M., Young A. B. Synthesis of a high specific activity 125I-labeled analog of PK 11195, potential agent for SPECT imaging of the peripheral benzodiazepine binding site. Int J Rad Appl Instrum B. 1989;16(4):423–429. doi: 10.1016/0883-2897(89)90111-6. [DOI] [PubMed] [Google Scholar]
  9. Glennon R. A., Yousif M. Y., Ismaiel A. M., el-Ashmawy M. B., Herndon J. L., Fischer J. B., Server A. C., Howie K. J. Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity sigma ligands. J Med Chem. 1991 Dec;34(12):3360–3365. doi: 10.1021/jm00116a003. [DOI] [PubMed] [Google Scholar]
  10. Hanson R. N., Franke L. A., Webb N. Radioiodinated 1-(diethylaminopropyl)-4-phenylpiperazine: a potential brain imaging agent. Int J Nucl Med Biol. 1985;12(5):397–400. doi: 10.1016/s0047-0740(85)80011-5. [DOI] [PubMed] [Google Scholar]
  11. Hanson R. N., Hassan M. Phenylpiperazine-based radiopharmaceuticals for brain imaging. 3. Synthesis and evaluation of radioiodinated 1-alkyl-4-phenylpiperazines. J Med Chem. 1987 Jan;30(1):29–34. doi: 10.1021/jm00384a005. [DOI] [PubMed] [Google Scholar]
  12. Hanson R. N. Preparation and evaluation of radioiodinated phenylpiperazines as adrenomedullary imaging agents. Int J Nucl Med Biol. 1983;10(4):219–222. doi: 10.1016/0047-0740(83)90082-7. [DOI] [PubMed] [Google Scholar]
  13. Hanson R. N. Radioiodinated 1-carboxamidino-4-phenylpiperazine: a potential adrenal and myocardial imaging radiopharmaceutical. Int J Appl Radiat Isot. 1982 Aug;33(8):629–632. doi: 10.1016/0020-708x(82)90060-6. [DOI] [PubMed] [Google Scholar]
  14. Hanson R. N. Radioiodinated 1-substituted-4-phenylpiperazines as potential brain imaging agents. Int J Nucl Med Biol. 1985;12(4):315–320. doi: 10.1016/0047-0740(85)90186-x. [DOI] [PubMed] [Google Scholar]
  15. Hoefnagel C. A., Voûte P. A., de Kraker J., Marcuse H. R. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma. Diagn Imaging Clin Med. 1985;54(1):21–27. [PubMed] [Google Scholar]
  16. Hoyer D., Neijt H. C. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol Pharmacol. 1988 Mar;33(3):303–309. [PubMed] [Google Scholar]
  17. Kimmig B., Brandeis W. E., Eisenhut M., Bubeck B., Hermann H. J., zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med. 1984 Jul;25(7):773–775. [PubMed] [Google Scholar]
  18. Lashford L. S., Lewis I. J., Fielding S. L., Flower M. A., Meller S., Kemshead J. T., Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992 Dec;10(12):1889–1896. doi: 10.1200/JCO.1992.10.12.1889. [DOI] [PubMed] [Google Scholar]
  19. Letiec A., Guilloteau D., Huguet F., Baulieu J. L., Besnard J. C., Viel C. Iodo carboxamidino-1 phenyl-4 piperazine un nouvel agent potentiel pour l'imagerie de la medullosurrenale: comparaison avec la meta iodobenzylguanidine. Int J Nucl Med Biol. 1986;12(6):495–496. [PubMed] [Google Scholar]
  20. Lloyd K. G., Depoortere H., Scatton B., Schoemaker H., Zivkovic B., Manoury P., Langer S. Z., Morselli P. L., Bartholini G. Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action. Pharmacol Biochem Behav. 1985 Oct;23(4):645–652. doi: 10.1016/0091-3057(85)90432-0. [DOI] [PubMed] [Google Scholar]
  21. Lyon R. A., Titeler M., McKenney J. D., Magee P. S., Glennon R. A. Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630–634. doi: 10.1021/jm00155a008. [DOI] [PubMed] [Google Scholar]
  22. Maj J., Lewandowska A. Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm. 1980 Jul-Aug;32(4):495–504. [PubMed] [Google Scholar]
  23. McEwan A. J., Shapiro B., Sisson J. C., Beierwaltes W. H., Ackery D. M. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med. 1985 Apr;15(2):132–153. doi: 10.1016/s0001-2998(85)80022-2. [DOI] [PubMed] [Google Scholar]
  24. Oepen G., Bork A., Jakovlev V., Nickel B., Thiemer K., Engel J. Neue analgetisch wirksame N'-acylierte Phenylpiperazine. Arzneimittelforschung. 1988 Nov;38(11):1549–1552. [PubMed] [Google Scholar]
  25. Ott R. J., Tait D., Flower M. A., Babich J. W., Lambrecht R. M. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol. 1992 Sep;65(777):787–791. doi: 10.1259/0007-1285-65-777-787. [DOI] [PubMed] [Google Scholar]
  26. Pettibone D. J., Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol. 1984 May 1;33(9):1531–1535. doi: 10.1016/0006-2952(84)90424-6. [DOI] [PubMed] [Google Scholar]
  27. Pranzatelli M. R., Balletti J. Serotonin receptors in human neuroblastoma: a possible biologic tumor marker. Exp Neurol. 1992 Mar;115(3):423–427. doi: 10.1016/0014-4886(92)90207-7. [DOI] [PubMed] [Google Scholar]
  28. Samanin R., Mennini T., Ferraris A., Bendotti C., Borsini F., Garattini S. Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):159–163. doi: 10.1007/BF00499059. [DOI] [PubMed] [Google Scholar]
  29. Troncone L., Rufini V., Montemaggi P., Danza F. M., Lasorella A., Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med. 1990;16(4-6):325–335. doi: 10.1007/BF00842788. [DOI] [PubMed] [Google Scholar]
  30. Vaidyanathan G., Zalutsky M. R. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem. 1992 Nov-Dec;3(6):499–503. doi: 10.1021/bc00018a006. [DOI] [PubMed] [Google Scholar]
  31. Watling K. J. Radioligand binding studies identify 5-HT3 recognition sites in neuroblastoma cell lines and mammalian CNS. Trends Pharmacol Sci. 1988 Jul;9(7):227–229. doi: 10.1016/0165-6147(88)90145-9. [DOI] [PubMed] [Google Scholar]
  32. Wigley D. B., Lyall A., Hart K. W., Holbrook J. J. The greater strength of arginine: carboxylate over lysine carboxylate ion pairs implications for the design of novel enzymes and drugs. Biochem Biophys Res Commun. 1987 Dec 31;149(3):927–929. doi: 10.1016/0006-291x(87)90497-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES